Trinity Biotech (NASDAQ:TRIB) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Trinity Biotech Stock Up 1.3%

TRIB opened at $0.85 on Friday. Trinity Biotech has a 52-week low of $0.48 and a 52-week high of $3.55. The company has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.87. The company has a market cap of $15.30 million, a P/E ratio of -0.37 and a beta of 0.86.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its stake in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent SEC filing. Institutional investors and hedge funds own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.